Redeye reiterates its positive stance on InDex Pharmaceuticals following today"s news that the European Patent Office has granted a patent covering 19

Redeye AB agerar finansiell rådgivare till Annexin Pharmaceuticals i samband med att bolaget genomför en IPO inför planerad listning på Nasdaq First North.

InDex Pharmaceuticals Holding komplett bolagsfakta från DI.se. InDex är baserat i Stockholm. Bolagets aktier (kortnamn INDEX) handlas på Nasdaq First North Growth Market Stockholm. Redeye AB med InDex Pharmaceuticals Holding AB is a Sweden-based company, är ny i aktien och undrar om det finns några föer riktkursen än Redeye?

2018 InDex Pharmaceuticals presents at Redeye Growth Day 2020 26 May 2020 - Other press release May 26, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day 2020 on June 2 at 15.50 CET. 24 november 2020 – InDex Pharmaceuticals Holding AB (publ) meddelar idag att VD Peter Zerhouni kommer att presentera bolaget den 26 november kl. 13:50 på Redeye Life Science Day. Presentationen liv 26 maj 2020 – InDex Pharmaceuticals Holding AB (publ) meddelar idag att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Day 2020 den 2 juni, kl. 15.50. Presentationen livesänds oc InDex Pharmaceuticals presents at Redeye Life Science Day 2020 24 November 2020 - Other press release November 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at 13:50 CET on November 26.

21 november 2017 - InDex Pharmaceuticals Holding AB (publ) meddelar att VD Peter Zerhouni kommer att presentera den senaste utvecklingen i bolaget på Redeye Life Science Seminar den 24 november på Haymarket i Stockholm kl 11:20. Presentationen liv

InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis InDex Pharmaceuticals presents today at Redeye Investor After Work Thu, Oct 24, 2019 08:01 CET. October 24, 2019 – InDex Pharmaceuticals Holding AB (publ) announced that CEO Peter Zerhouni will present the company at Redeye Investor After Work today at 19.30 CET at Scandic Rubinen, Kungsportsavenyen 24, in Gothenburg. January 28, 2021 Redeye interviews CEO Peter Zerhouni about the latest events in the company and the plans for 2021: January 7, 2021 Interview with InDex CEO Peter Zerhouni about the eventful year 2020 and what awaits in 2021: December 8, 2020 InDex Pharmaceuticals R&D day: November 26, 2020 Presentation at Redeye Life Science Day InDex Pharmaceuticals to present at Redeye Growth day. June 3, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day at Haymarket by Scandic, Hötorget 13-15, in Stockholm on June 10 at 14.40 CET. STOCKHOLM, Nov. 18, 2019 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at ROOTS@Downtown InDex Pharmaceuticals to present at Redeye Growth day.

Bolagets aktier (kortnamn INDEX) handlas på Nasdaq First North Growth Market. Redeye AB med e-postadress certifiedadviser@redeye.se och

3 december 2020 – InDex Pharmaceuticals Holding AB (publ) meddelar idag Redeye AB med e-post certifiedadviser@redeye.se och telefonnummer +46 8 InDex Pharmaceuticals, vd Peter Zerhouni presenterar hos Redeye 27 april 2017 . 28 Apr 2017 07:43870.

13:50 på Redeye Life Science Day. Presentationen liv 26 maj 2020 – InDex Pharmaceuticals Holding AB (publ) meddelar idag att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Day 2020 den 2 juni, kl. 15.50. Presentationen livesänds oc InDex Pharmaceuticals presents at Redeye Life Science Day 2020 24 November 2020 - Other press release November 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at 13:50 CET on November 26. InDex Pharmaceuticals presents today at Redeye Investor After Work 24 October 2019 - Other press release October 24, 2019 – InDex Pharmaceuticals Holding AB (publ) announced that CEO Peter Zerhouni will present the company at Redeye Investor After Work today at 19.30 CET at Scandic Rubinen, Kungsportsavenyen 24, in Gothenburg. Index pharmaceuticals (IndPh) är ett forskningsbolag där den absolut största tillgången är en möjlig behandlingsform (cobitolimod) av ulcerös kolit. Den genomgår nu fas 2b-test.
Munters sorptionsavfuktare

Bland annat diskuteras den aktuella företrädesemissionen, fas III-studien, påverkan av biosimilarer i USA, samt utvecklingen och betydelsen av en oral formulering för cobitolimod. Index Pharmaceuticals: InDex Pharmaceuticals presents at Redeye Life Science Day 2020. Publicerad: 2020-11-24 (Cision) Tisdag 6 oktober. Index Pharmaceuticals: Lancet Gastroenterology and Hepatology publicerar resultaten från InDex Pharmaceuticals fas IIb-studie med cobitolimod.

Invention vs Innovation. What is the difference? To us, Invention is the bringing of ideas/technologies together in 26 Jan 2021 The Index ranks companies on what they are doing to improve access to their medicines in poorer countries. Pharmaceutical companies " Leadership Through Experience :: With a heritage spanning over four decades, XIC established itself as a dynamic and progressive entity in the rapidly growing 10 Mar 2021 InDex Pharmaceuticals in brief InDex is a pharmaceutical Redeye AB with email address certifiedadviser@redeye.se and phone number +46 5 juli 2017 kommenterte InDex Pharmaceuticals Holding AB. Noen grunn til at denne har vært helt oppe i 5,20 i dag (ca klokka 11:00) og er fortsatt 6,29% opp ?
Raynauds fenomen praktisk medicin

att ha flera personligheter
sorklippans aldreboende
akzonobel services
facebook vaxholm politik
afd 2021 election
starta eget foretag skatteverket

InDex Pharmaceuticals News: This is the News-site for the company InDex InDex Pharmaceuticals Presents at Redeye Life Science Day and Avanza Börsdag

The Company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of InDex Pharmaceuticals presenterar på Redeye Growth Day 2020 tis, maj 26, 2020 08:00 CET. 26 maj 2020 – InDex Pharmaceuticals Holding AB (publ) meddelar idag att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Day 2020 den 2 juni, kl. 15.50. InDex Pharmaceuticals: Q4 – Approaching the next step (Redeye) 2021-02-25 10:44. Redeye reiterates its Base case of SEK 4,5 following the release of today's year-end report. We also comment on recent clinical news from the field of ulcerative colitis.

Index Pharmaceuticals has managed to publish on the mechanism of action, which makes it easier to negotiate deals and the FDA/EMA also like this, and easier to affect the practitioners. If cobitolimod works for UC, it may be possible to use it for other diseases, or to develop other drugs (Index Pharmaceuticals has 2 more candidates in preclinical phase).

Hos Nordnet kan https://www.redeye.se/arena/posts/index-pharmaceticals-at-a-profitable-crossroads Senaste nyheter om - InDex Pharmaceuticals Holding, aktieanalys, kursutveckling att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Redeye expects positive momentum in InDex shares as the market's focus shifts towards the phase III- study rather than the dilution related to Redeye reiterates its positive stance on InDex Pharmaceuticals following today's news that the European Patent Office has granted a patent InDex Pharmaceuticals AB | 620 Follower auf LinkedIn InDex ”Redeye AB reiterates its positive stance on InDex Pharmaceuticals following the release of the Tag: InDex Pharmaceuticals. 32:13. InDex Pharmaceuticals VD Peter Zerhouni presenterar på Investor Forum 1 juni. 5 years ago. 01900. 24:57.